Amniotic membrane preparations and purified compositions and anti-inflammation methods
Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.
1. A method of reducing inflammation in a subject in need thereof, comprising administering to the subject a composition comprising a water-soluble extract of amniotic membrane from frozen or previously frozen placenta, wherein the water-soluble extract comprises tumor necrosis factor-stimulated gene 6 (TSG-6), pentraxin (PTX-3), thrombospondin (TSP-1), and cross-linked high molecular weight hyaluronan (HA).
2. The method of claim 1 , wherein the subject has inflammation associated with vascular diseases, migraine headaches, tension headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, scleroderma, rheumatic fever, type I diabetes, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, ischemia, a brain disorder, Parkinson's disease, Alzheimer's disease, chronic inflammation associated with cranial radiation injury, acute inflammatory conditions resulting from infection, chronic inflammatory conditions resulting from asthma, or inflammation associated with trauma.
3. The method of claim 1 , wherein the subject has an inflammatory disorder.
4. The method of claim 3 , wherein the inflammatory disorder is arthritis, asthma, atherosclerosis, osteoporosis, bronchitis, tendonitis, bursitis, a skin inflammation disorder, enuresis, eosinophilic disease, a gastrointestinal disorder, or non-cardiac chest pain.
5. The method of claim 4 , wherein the arthritis is rheumatoid arthritis, osteoarthritis, spondyloarthopathy, gouty arthritis, degenerative joint disease, systemic lupus erythematosus, Sjogren's syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet's disease, haemolytic autoimmune anaemia, multiple sclerosis, amyotrophic lateral sclerosis, amylosis, acute painful shoulder, psoriatic, or juvenile arthritis.
6. The method of claim 4 , wherein the skin inflammation disorder is psoriasis, eczema, burns, or dermatitis; or
the gastrointestinal disorder is inflammatory bowel disease, peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, Crohn's disease, gastritis, diarrhea, irritable bowel syndrome, ulcerative colitis, gastroesophageal reflux disease, eosinophilic esophagitis, gastroparesis, non-ulcerative dyspepsia, or additional food intolerances and food allergies related bowel disorders.
7. The method of claim 1 , wherein the subject has arthritis.
8. The method of claim 1 , wherein the extract further comprises Smad7.
9. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable diluent, excipient, carrier, or combination thereof.
10. The method of claim 9 , wherein the composition is formulated as a non-solid dosage form, a solution, drops, suspension, aerosol, paste, spray, ointment, oil, emulsion, cream, lotion, gel, a coated bandage, a patch, sticks, balms, or shampoo.
11. The method of claim 9 , wherein the composition is formulated for ophthalmic administration, systemic administration, or topical administration.
12. The method of claim 9 , wherein the composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjuctival injection, retrobulbar injection, intracameral injection, sub-Tenon's injection, implantation, ocular implantation, or ocular insertion.
13. The method of claim 9 , wherein the composition further comprises a penetration enhancer and an aqueous adjuvant.
14. The method of claim 9 , wherein the composition is formulated as a solid dosage form.
15. The method of claim 9 , wherein the composition is formulated for controlled release.